Sequel Med Tech develops next-generation drug-delivery technology for diabetes care, with a focus on automated insulin delivery systems. The company's work spans insulin pump engineering, medical device development and algorithm-driven dosing software. Its flagship product, twiist, is an FDA-cleared Automated Insulin Delivery (AID) system for people with type 1 diabetes. Sequel describes it as the first drug-delivery technology that directly measures the volume of insulin delivered with every microdose.
twiist is powered by the Tidepool algorithm, which places software and control systems at the centre of the product. The company reports more than 40 years of innovation heritage in insulin delivery and operates in the United States, across the healthcare, medical devices, diabetes care and drug-delivery sectors.
Sequel describes its team as innovators and problem solvers with a mission-driven focus on transforming diabetes care, and states a commitment to accessible, affordable and personalised care. The company supports the diabetes community through employer benefit programmes and says it values strategic partnerships to expand access.
